After the discovery of the JAK2 V617F mutation in MPN patients, several other mutations in the JH2 domain of JAKs have been identified in MPN, but also in lymphoid and myeloid leukemia and multiple myeloma patients [14], [39]. This evidence concerns the gene JAK2 and myeloproliferative neoplasm.